NCT02210078View on ClinicalTrials.gov

Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

February 19, 2015

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Cytomegaloviral InfectionHematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
Interventions
BIOLOGICAL

Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER